Skip to main content
Signal8

Vu Quan Anh

SEC insider (Form 3/4/5 filer). CIK 0001892297. Chief Financial Officer at Monopar Therapeutics (MNPR). 8 reported Form 4/5 transactions since Sep 2024; latest on Sep 30, 2026. Located in WILMETTE, IL.

Companies Vu Quan Anh has filed insider reports for

  • Monopar Therapeutics (MNPR): Officer, Chief Financial Officer
Vu Quan Anh profile photo

Vu Quan Anh

CIK: 0001892297

Transaction Breakdown

Open Market Buys (P)1 (12.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (25.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)2 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Monopar Therapeutics logo
MNPR

Monopar Therapeutics

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

  • Monopar Therapeutics logo
    MNPR

    Monopar Therapeutics

    Sep 30, 2026
    Exercise
    Direct
    614 shares-
  • Monopar Therapeutics logo
    MNPR

    Monopar Therapeutics

    Sep 30, 2026
    Tax Payment
    Direct
    180 shares at avg. $79.67$14K
  • Monopar Therapeutics logo
    MNPR

    Monopar Therapeutics

    Jun 30, 2026
    Tax Payment
    Direct
    507 shares at avg. $92.59$47K
  • Monopar Therapeutics logo
    MNPR

    Monopar Therapeutics

    Jun 30, 2026
    Exercise
    Direct
    1.2K shares-
  • Monopar Therapeutics logo
    MNPR

    Monopar Therapeutics

    Dec 26, 2025
    Purchase
    Direct
    1.5K shares at avg. $69.95$105K
  • Monopar Therapeutics logo
    MNPR

    Monopar Therapeutics

    Dec 2, 2025
    Award

    Stock Options

    Direct
    7.1K shares-
  • Monopar Therapeutics logo
    MNPR

    Monopar Therapeutics

    Dec 2, 2025
    Award

    Restricted Stock Units

    Direct
    9.8K shares-
  • Monopar Therapeutics logo
    MNPR

    Monopar Therapeutics

    Mar 3, 2025
    Award

    Stock Options

    Direct
    25K shares-

1-8 of 8